Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crotonoside is a naturally occurring nucleoside analogue, specifically an isoguanosine derivative, originally isolated from the seeds of *Croton tiglium* L. It is currently being investigated for its potential as an anti-leukemic agent, particularly in acute myeloid leukemia (AML). Crotonoside exerts its effects through multiple mechanisms, including the inhibition of FLT3 activation, reduction of HDAC3 and HDAC6 expression, and downregulation of APOBEC3G. It also disrupts DNA synthesis and causes mitochondrial dysfunction by inhibiting mitochondrial DNA polymerase γ, leading to the accumulation of reactive oxygen species (ROS) and the induction of ferroptosis via the p62/KEAP1 autophagy pathway. Historically, crotonoside has been recognized as a bioactive component in traditional medicine for treating conditions such as constipation, inflammation, and rheumatism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on crotonoside.